Who are we?
Neopharm Israel is dedicated to the marketing and sales of premium ethical prescription products – pharmaceuticals, orphan drugs and biologic drugs.
Neopharm Israel is the exclusive representative and partner of leading multinational bio-pharma and consumer healthcare brands including: Alexion, Celgene, Fresenius, Shire.
Neopharm Israel has a strong track record of success in new products launches and maintains the ability to venture into new medical fields swiftly and successfully, achieving and maintaining high market share and leading market positions. Through its home therapy division Home Cure, Neopharm Israel provides advanced medical services to patients in the comfort of their home through a team of highly trained healthcare professionals.
Drugs Disributed by Neopharm Scientific Ltd
Romidepsin 10 mg/vial. 1 vial 10 mg of romidepsin +1 diluent vial.
Admin. 14 mg/m2 IV over a 4-hour per. on days 1, 8, and 15 of a 28-day cycle. Repeat every 28 days if ptt. continues to benefit from and toler. the drug.
Tmt. of cutaneous T-cell lymphoma (CTCL) in pts. who have received at least one prior syst. ther. Tmt. of periph. T-cell lymphoma (PTCL) in pt. who have received at least one prior ther.
C/I:Hypersens.
Protein Kinase Inhibitor. Lenvatinib (as mesilate) 4 mg, 10 mg. HARD CAPS.: 30. Different. thyroid carcinoma (DTC): 24 mg (two 10 mg caps. and one 4 mg cap.) once dly. The dly. dose is to be modified as needed accord. to the dose/toxicity manag. plan.
Clear cell renal cell carcinom. (RCC): 18 mg (one 10 mg cap. and two 4 mg caps.) once dly. in comb. with 5 mg of everolimus once dly. The dly. doses of lenvatinib and, if necessary, everolimus are to be modified as needed accord. to the dose/toxicity manag. plan.
Hepatocellular Carcinoma (HCC): 8 mg (two 4 mg caps.) once dly. for pts. with a bdy. weight of<60 kg & 12 mg (three 4 mg caps.) once dly. for pts. with a body weight of≥60 kg. Dose adjust. are based only on toxicit. observed and not on body weight changes during tmt. The dly. dose is to be modified, as needed, according to the dose/toxicity manag. plan.
Dose adjust. and Discont. for HCC Manag. of some ADR's may require dose interrupt., adjust., or discont. See lit.
Tmt. of adult pts. with progress., locally advance. or metastat., differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refract. to radioact. iodine (RAI).
In comb. with everolimus for the tmt. of adult pts. with advanc. clear cell renal cell carcinom. (RCC) follow. one prior vascul. endothelial growth factor (VEGF)-targeted ther.
Indicated as monother. for the tmt. of adult pts. with advanc. or unresect. hepatocellular carcinom. (HCC) who have received no prior system. ther.
C/I: Hypersens. Lact.
Immunomodulator. Lenalidomide 2.5, 5, 7.5, 10, 15, 20, 25 mg. CAPS: 21 x 5 mg, 10 mg, 15 mg, 25
mg. Initial: 25 mg dly with water as
single cap on days 1-21 of repeated 28
day cycles. Not to be broken, chewed/
opened. In comb. with
dexamethasone: 40 mg dly on days
1-4, 9-12 and 17-20 of ea. 28 day cycle
for first 4 cycles of ther., foll. by 40 mg
dly on days 1-4 every 28 days.
Lenalidomide in comb. with
dexamethasone, is an option for tmt. of
multiple myeloma in pts. who have
received at least one prior therapy.
C/I: Pregn. category X: Lenalidomide is
an analog of thalidomide, a known
human theratogen that causes severe,
life-threaten. human birth defects.
See lit.
Retinoid. Alitretinoin 10 mg, 30 mg. SOFT CAPS.: 30. The recomm. dose is 10 mg or 30 mg ×1/d. Recom. init. dose is 30 mg ×1/d. A dose reduction to 10 mg ×1/d may be consid. in pts. with unacceptab. ADR's. to the 30 mg dose. See lit.
Durat. of tmt.: A tmt. course may be given for 12-24 wks. depend. on response. Discont. of ther. is recomm. in pts. who have achieved clear or almost clear hands earlier than 24 wks. Discont. of ther. should also be consid. for pts. who still have severe dis. after the init. 12 wks. of contin. tmt.
The caps. should be taken with a main meal once dly., preferab. at the same time each day.
Adult. who have severe chron. hand eczema that is unrespons. to tmt. with potent topic. corticosteroids.
Pts. in whom the eczema has predominant. hyperkeratotic features are more likely to respond to tmt. than in those in whom the eczema predominan. presents as pompholyx.
C/I: Pregn. is an absolute contraind. Woman of childbear. potent. unless all of the condit. of the Preg. Prevention Programme are met. See lit. Pts. who are allerg. to peanut, soya or with rare heredit. fructose intoler. Lactat. women. Pts. with hep. insuffic., severe ren. insuffic., uncontroll. hypercholesterolem., uncontroll. hypertriglyceridemia, uncontroll. hypothyroidism, hypervitaminosis A. Hypersens. to alitretinoin, other retinoids. Receiv. concom. tmt. with tetracyclines.
